Kingworld Medicines Group Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Li Sheng Zhao
Algemeen directeur
CN¥1.5m
Totale compensatie
| Percentage CEO-salaris | 98.5% |
| Dienstverband CEO | 16.2yrs |
| Eigendom CEO | 54.0% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 14yrs |
Recente managementupdates
Recent updates
Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt
Oct 04
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338
May 31Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely
May 22Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings
Apr 29Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338
Apr 23A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Mar 22The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising
Nov 30Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement
Aug 17Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247
May 30The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing
May 11Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247
Apr 03Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture
Feb 07A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)
Oct 07Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business
Jul 05Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024
Apr 27We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)
Aug 17Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly
Apr 24Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)
Mar 29Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares
Mar 08Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?
Feb 15Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)
Jan 25
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?
Dec 18We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt
Dec 05What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation
Nov 22Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥31m |
| Mar 31 2024 | n/a | n/a | CN¥35m |
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥38m |
| Sep 30 2023 | n/a | n/a | CN¥37m |
| Jun 30 2023 | n/a | n/a | CN¥36m |
| Mar 31 2023 | n/a | n/a | CN¥29m |
| Dec 31 2022 | CN¥1m | CN¥1m | CN¥23m |
| Sep 30 2022 | n/a | n/a | CN¥29m |
| Jun 30 2022 | n/a | n/a | CN¥35m |
| Mar 31 2022 | n/a | n/a | CN¥33m |
| Dec 31 2021 | CN¥1m | CN¥1m | CN¥30m |
| Sep 30 2021 | n/a | n/a | CN¥26m |
| Jun 30 2021 | n/a | n/a | CN¥21m |
| Mar 31 2021 | n/a | n/a | CN¥17m |
| Dec 31 2020 | CN¥1m | CN¥1m | CN¥12m |
| Sep 30 2020 | n/a | n/a | CN¥16m |
| Jun 30 2020 | n/a | n/a | CN¥20m |
| Mar 31 2020 | n/a | n/a | CN¥32m |
| Dec 31 2019 | CN¥2m | CN¥2m | CN¥43m |
| Sep 30 2019 | n/a | n/a | CN¥45m |
| Jun 30 2019 | n/a | n/a | CN¥46m |
| Mar 31 2019 | n/a | n/a | CN¥44m |
| Dec 31 2018 | CN¥1m | CN¥1m | CN¥41m |
| Sep 30 2018 | n/a | n/a | CN¥49m |
| Jun 30 2018 | n/a | n/a | CN¥56m |
| Mar 31 2018 | n/a | n/a | CN¥54m |
| Dec 31 2017 | CN¥2m | CN¥1m | CN¥51m |
Compensatie versus markt: De totale vergoeding ($USD 202.28K ) Li Sheng } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 236.00K ).
Compensatie versus inkomsten: De vergoeding van Li Sheng is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Li Sheng Zhao (66 yo)
16.2yrs
Tenure
CN¥1,452,000
Compensatie
Mr. Li Sheng Zhao is a Co-founder of Kingworld Medicines Group Limited and serves as its Chief Executive Officer. Mr. Zhao is responsible for Kingworld Medicines Group's overall strategic planning and busi...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 16.2yrs | CN¥1.45m | 54.04% HK$ 157.1m | |
| Co-Founder & Executive Director | 16.2yrs | CN¥1.32m | 15.23% HK$ 44.3m | |
| Executive Director | 15.3yrs | CN¥483.00k | 0.45% HK$ 1.3m | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | 0.036% HK$ 103.9k | |
| Independent Non-Executive Director | 14yrs | CN¥285.00k | geen gegevens | |
| Independent Non-Executive Director | 11.3yrs | CN¥285.00k | 0.042% HK$ 121.5k | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens |
14.0yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1110 zijn ervaren en ervaren (gemiddelde ambtstermijn van 14 jaar).